ARCHIVES

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

This article is from The Cancer Letter archive.

Vol. 25 No. 30 | July 30, 1999

Download PDF Visit The Full Archive

Related Articles

DCT Board Ok’s PA, BRM Contract Concepts

October 30, 1992

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

The Philadelphia Story: How Surprise Filing by Abramson Spurred Penn to Follow Suit

March 16, 2012

Black Women More Likely To Delay Diagnosis, Treatment

July 29, 2005

Herceptin With Chemo Increases Survival In Early-Stage Breast Cancer, Study Finds

December 30, 2005

NeoPharm To Begin Phase III Trial For Glioblastoma

December 26, 2003